Revolution Medicines officer sells 1,764 shares

RVMD’s Chief Global Commercialization Officer sold 1,764 shares under a pre-arranged Rule 10b5-1 trading plan, retaining 40,352 shares afterward.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported that its Chief Global Commercialization Officer, Anthony Mancini, sold 1,764 shares of common stock on September 18, 2026 in a sale described as an open-market or private transaction at $196.94 per share. Following this sale, he held 40,352 shares directly. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.

Insider Trade Summary 10b5-1

Net Seller: 1,764 shares

Net Sell 1 txn

Insider Mancini Anthony

Role See Remarks

Sold 1,764 shs ($347K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	1,764	$196.94	$347K

Holdings After Transaction: Common Stock — 40,352 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.

Key Figures

Shares sold: 1,764 shares Sale price per share: $196.94 per share Shares held after sale: 40,352 shares +1 more

4 metrics

Shares sold 1,764 shares Common stock sold by Anthony Mancini on September 18, 2026

Sale price per share $196.94 per share Price for the 1,764 RVMD shares sold on September 18, 2026

Shares held after sale 40,352 shares Direct holdings of Anthony Mancini following the September 18, 2026 sale

Rule 10b5-1 plan adoption date June 11, 2026 Date Anthony Mancini adopted the trading plan covering the reported sale

Key Terms

Common Stock, Rule 10b5-1 trading plan, open-market or private transaction

3 terms

Common Stock financial

"sold 1,764 shares of common stock on September 18, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market or private transaction financial

"a sale described as an open-market or private transaction at $196.94 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD report for Anthony Mancini?

Revolution Medicines reported that Chief Global Commercialization Officer Anthony Mancini sold 1,764 shares of common stock on September 18, 2026 at $196.94 per share in an open-market or private transaction, and held 40,352 shares directly afterward.

Was the RVMD insider sale by Anthony Mancini under a Rule 10b5-1 plan?

Yes. The filing states the sale by Anthony Mancini was made pursuant to a Rule 10b5-1 trading plan that he adopted on June 11, 2026, indicating the transaction followed a pre-arranged trading schedule.

How many RVMD shares did Anthony Mancini hold after the reported sale?

After the reported sale, Anthony Mancini directly held 40,352 shares of Revolution Medicines common stock. This figure reflects his holdings immediately following the 1,764-share sale on September 18, 2026.

What was the sale price for the RVMD shares sold by Anthony Mancini?

The reported sale price for the shares sold by Anthony Mancini was $196.94 per share. The sale involved 1,764 shares of Revolution Medicines common stock on September 18, 2026 in an open-market or private transaction.

What is Anthony Mancini’s role at Revolution Medicines (RVMD)?

Anthony Mancini is identified as the Chief Global Commercialization Officer of Revolution Medicines, Inc. in the filing, and he is reported as an officer of the company rather than a director or ten percent owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 06:00 PM Accepted by SEC EDGAR 09/22/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Anthony

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/18/2026		S(1)		1,764	D	$196.94	40,352	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.

Remarks:

Chief Global Commercialization Officer

	/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)